. Mouse number and measurement accuracy of categorical responses defined by the 5-cat criteria. (a-c): individual mouse response and majority response in PDX (a), CDX (b) and syngeneic models (c), x axis is the number of majority response from 4 response categories (MCR: maintained complete response, CR: complete response, PR: partial response, SD: stable disease, PD: progressive disease.), y axis is the percentage of individual mouse response relative to the majority (average  s.d.). There are 26,127 mice in 2,883 unique treatment PDX models, 11,139 mice in 1,219 unique treatment CDX models, and 5,945 mice in 637 unique treatment syngeneic models. Each unique treatment model had at least 8 mice.
(d-g): measurement accuracy increases with number of mice for PDX (d), CDX (e) and syngeneic models (f). For each unique treatment model, the majority response of n (n=1, 3, 5, 7 in x axis) randomly sampled mice was obtained to see if it agreed with the actual majority response. The procedure was repeated 1,000 times to obtain the accuracy-percentage of times (average  s.d.) that they agreed-for 4 response categories (excluding CR), whose unweighted average is shown in (g). . A smaller AUC ratio indicates better drug efficacy. When the ratio is negative, tumor shrinks under drug treatment; when the ratio is larger than 1, tumor grows faster under drug treatment. We can use the trapezoidal rule to obtain AUCs from the growth curves, even when they are nonexponential, for which AUC is a measure of average or aggregated drug effect during study period. Similar to TGI, AUC ratio varies more in the first days before reaching stable response. Unlike TGI that approaches 1 with time, AUC ratio converges to a value, which is ⁄ under exponential growth kinetics, and which may be far away from 1, as shown from a MCT of 50 PDXs (c-d, cf. Figure S12 ). ) between log-transformed tumor volume and day is dependent on tumor growth, which is measured by relative tumor volume, or RTV, between ending day and starting day. R 2 is smallest when the TV ratio is around 1, at which there is, by definition, no correlation. R 2 increases quickly when RTV goes down and up. The percentage of growth curves with R 2 >0.50 is 96.7%, 98.3%, and 98.7% when RTV is larger than 2, 3, and 4, respectively. If RTV is less than 0.5, 85.7% of growth curves have R 2 >0.50. Therefore, under drug treatment, most tumors either do not grow (or shrink) much, or grow (or shrink) exponentially that can be well modelled by Equations 1 in Materials and Methods. (1), for patients with IHC score greater than ~200, the 7 patients receiving cetuximab in addition to had significantly longer (a) PFS (8.1 ± 6.1 months, one-sided Mann-Whitney U-test p-value=0.03) and (b) OS (19.5 ± 12.0 months, p-value=0.02) than the 19 patients receiving only chemotherapies (PFS= 4.1 ± 3.2 months, OS=10.1 ± 7.8 months). Two censored patients with very low OS and PFS in the chemotherapy group were excluded from the analysis. Data were based on the supplemental Figure A1 ≤ . In a graph, each line has the same ⁄ value. For the red lines, ⁄ ranges from 1 to 0 with 0.1 stepwise decrease from bottom to top. For the blue lines, ⁄ ranges from -1 to 0 with 0.1 stepwise increase from top to bottom. For clarify, the blue and red lines at ⁄ = 0 are drawn with slight separation. Gray portion of the lines means that the tumor volumes are larger than 3000mm 3 , at which mice are sacrificed and TGIs no longer exist. (d-e) TGIs at 6 measurement days for the first 4 PDXs in a MCT. TGI increases by day when it is between 0 and 1. A strong positive correlation is observed between tumor growth rate kc and TGI at day 17 for 24 PDXs whose TGIs are between 0 and 1 for all measurement days. (f-g) TGIs at 6 measurement days for the first 4 PDXs in a second MCT. TGI decreases by day when it is greater than 1. A strong negative correlation is observed between tumor growth rate kc and TGI at day 17 for 18 PDXs whose TGIs are greater than 1 at all measurement days. 
